nach oben

Drugs

Erschienen in:

01.08.2010 | Adis Drug Profile

Oral Bepotastine

In Allergic Disorders

verfasst von: Katherine A. Lyseng-Williamson

Erschienen in: Drugs | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Oral bepotastine is a second-generation histamine H₁ receptor antagonist that also suppresses some allergic inflammatory processes.

Numerous short- and long-term clinical trials and surveillance studies have shown that twice-daily bepotastine is an effective and generally well tolerated antihistamine in the treatment of patients with allergic rhinitis, chronic urticaria or pruritus associated with skin conditions (eczema/dermatitis, prurigo or pruritus cutaneus).

Bepotastine 20 mg/day was significantly more effective than terfenadine 120 mg/day in patients with perennial allergic rhinitis, as evaluated by the final global improvement rating and several other endpoints in a phase III trial.

In phase III trials in patients with chronic urticaria, bepotastine 20 mg/day was more effective than placebo in improving levels of itching and eruption, and as effective as terfenadine 120 mg/day with regard to the final global improvement rating and other endpoints.

In a noncomparative trial in patients with pruritus associated with skin diseases, the majority of bepotastine recipients in the overall population, as well as in the specific skin disease subgroups (eczema/dermatitis, prurigo or pruritus cutaneus), had a final global improvement rating of moderate or greater.

Bepotastine was generally well tolerated in adult and paediatric patients with allergic conditions.

Bousquet J, Reid J, van Weel C, et al. Allergic rhinitis management pocket reference 2008. Allergy 2008; 63(8): 990–6CrossRefPubMed

Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GAL²EN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64(10): 1427–43CrossRefPubMed

Furukawa F. Atopic dermatitis and urticaria: for the prevention and cure via disease control and management [in Japanese]. Nippon Rinsho 2009 Nov; 67(11): 2152–6PubMed

Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 2006; 118(5): 985–96CrossRefPubMed

Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001; 108(2): S65–71CrossRefPubMed

Talion® tablets (bepotastine besilate): product information. Osaka: Tanabe Seiyaku Co., Ltd, 2006

Ishibashi Y, Kawashima M, Harada S, et al. Phase I study of antiallergic agent, TAU-284 (betotastine besilate): study of inhibitory effect on intradermal reaction of histamine [in Japanese]. Rinsho Iyaku 1997; 13(5): 1187–97

Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol 2004 Sep; 29(5): 526–32CrossRefPubMed

Tashiro M, Duan X, Kato M, et al. Brain histamine H₁ receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with ¹¹C-doxepin. Br J Clin Pharmacol 2008 Jun; 65(6): 811–21CrossRefPubMedPubMedCentral

10.

Yokota H, Mizuuchi H, Maki T, et al. Phase I study of TAU-284: single oral administration in healthy male volunteers [in Japanese]. Rinsho Iyaku 1997; 13(5): 1137–53

11.

Kadosaka T, Shiraishi K, Mizuuchi H, et al. Phase I study of TAU-284: repeated oral administration in healthy male volunteers [in Japanese]. Rinsho Iyaku 1997; 13(5): 1155–68

12.

Kumagai Y, Uchiumi M, Murasaki M, et al. Pharmaco-kinetics study of TAU-284 in elderly volunteers [in Japanese]. Rinsho Iyaki 1997; 13(5): 1169–85

13.

Hashiguchi K, Tang H, Fujita T, et al. Bepotastine besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO chamber). Expert Opin Pharmacother 2009 Mar; 10(4): 523–9CrossRefPubMed

14.

Ohta N, Akatsuka N, Saito F, et al. The effect of prophylactic treatment with bepotastine in patients with Japanese cedar pollinosis [in Japanese]. Pract Oto Rhino Laryngol 2002; 95(5): 531–7CrossRef

15.

Ukai K, Takeuchi M, Masuda S, et al. Clinical pharmacological study of antiallergic agent, TAU-284 (betotastine besilate): the effect on counting of eosinophils in nasal discharge and the patency improvement of nasal cavity [in Japanese]. Rinsho Iyaku 1997; 13(5): 1401–12

16.

Kawashima K, Sakai M, Takatsuka S, et al. Clinical pharmacokinetic study of Talion® tablet (bepotastine besilate) in nephropathic patients (post-marketing clinical trial) [in Japanese]. Rinsho Iyaku 2003; 19(6): 637–48

17.

Kato M, Nishida A, Aga Y, et al. Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate. Arzneimittelforschung 1997 Oct; 47(10): 1116–24PubMed

18.

Yato N, Murata T, Saito N, et al. Anti-allergic activity of betotastine besilate (TAU-284), a new anti-allergic drug [in Japanese]. Nippon Yakurigaku Zasshi 1997 Jul; 110(1): 19–29CrossRefPubMed

19.

Ueno M, Inagaki N, Nagai H, et al. Antiallergic action of betotastine besilate (TAU-284) in animal models: a comparison with ketotifen. Pharmacology 1998 Oct; 57(4): 206–14CrossRefPubMed

20.

Honda H. Inhibitory effect of betotastine on anaphylactic and histamine-induced reactions in guinea pigs [in Japanese]. Jpn Pharmacol Ther 1997; 25(4): 9–18

21.

Sakamoto O, Okanari E, Ueno H. Effect of betotastine on experimental asthma induced in guinea pigs [in Japanese]. Jpn Pharmacol Ther 1997; 25(4): 19–24

22.

Murata T, Matsumoto Y, Suzuki T, et al. Effect of betotastine besilate (TAU-284), a novel anti-allergic agent on experimental allergic rhinitis [in Japanese]. Jpn J Allergol 1997; 46(7): 576–84

23.

Andoh T, Kuraishi Y. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B₄ action in mice. Eur J Pharmacol 2006 Oct 10; 547(1-3): 59–64CrossRefPubMed

24.

Tanizaki H, Kambe N, Nakamura Y, et al. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int Arch Allergy Immunol 2008; 145(4): 277–82CrossRefPubMed

25.

Sakai A, Kikuchi M, Yato N, et al. Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Arzneimittelforschung 1997 Aug; 47(8): 954–8PubMed

26.

Shin’ichi S, SangJae B, Fumihide O. Bepotastine besilate suppresses ICAM-1 expression in vascular endothelial cells [in Japanese]. Jpn J Clin Exp Med 2006; 83(8): 1245–8

27.

SangJae B, Shin’ichi S. Suppression effect of bepotastine besilate on oxidative stress (nitric acid: NO) [in Japanese]. Jpn J Clin Exp Med 2008; 85(7): 1045–8

28.

Kaminuma O, Ogawa K, Kikkawa H, et al. A novel antiallergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells. Biol Pharm Bull 1998 Apr; 21(4): 411–3CrossRefPubMed

29.

Kobayashi M, Kabashima K, Nakamura M, et al. Down-modulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytes. Skin Pharmacol Physiol 2009; 22(1): 45–8CrossRefPubMed

30.

Ohashi R, Kamikozawa Y, Sugiura M, et al. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos 2006 May; 34(5): 793–9CrossRefPubMed

31.

Baba S, Takasaka T, Baba K, et al. Clinical trial of TAU-284 (betotastine besilate) on perennial allergic rhinitis: a double-blind study in comparison with terfenadine [in Japanese]. Rinsho Iyaku 1997; 13(5): 1307–35

32.

Kawashima M, Harada S, Nakashima M, et al. Phase III study of TAU-284 (bepotastine besilate) on chronic urticaria: a multicenter double-blind comparative study with placebo [in Japanese]. Rinsho Iyaku 2002; 18(4): 501–19

33.

Ishibashi Y, Harada S, Niimura M, et al. A multicenter double-blind comparative study; clinical evaluation of TAU-284 (betotastine besilate) on chronic urticaria using terfenadine as a control drug [in Japanese]. Rinsho Iyaku 1997; 13(5): 1287–306

34.

Ishibashi Y, Harada S, Niimura M, et al. Clinical evaluation of TAU-284 (betotastine besilate) on eczema/dermatitis, prurigo, and pruritus cutaneus [in Japanese]. Rinsho Iyaku 1997; 13(5): 1383–400

35.

Baba S, Sakakura Y, Iwata S, et al. Early phase II study of TAU-284 (betotastine besilate) on perennial allergic rhinitis [in Japanese]. Rinsho Iyaku 1997; 13(5): 1217–35

36.

Baba S, Takasaki T, Baba K, et al. Late phase II clinical study of TAU-284 for perennial allergic rhinitis: dose finding study by the double-blind method [in Japanese]. Rinsho Iyaku 1997; 13(5): 1259–86

37.

Ishibashi Y, Harada S, Niimura M, et al. Early phase II study of TAU-284 (betotastine besilate) on chronic urticaria [in Japanese]. Rinsho Iyaku 1997; 13(5): 1199–215

38.

Ishibashi Y, Harada S, Niimura M, et al. Late phase II study of TAU-284 (betotastine besilate) on chronic urticaria: optimal dose finding study by double-blind technique [in Japanese]. Rinsho Iyaku 1997; 13(5): 1237–57

39.

Baba S, Takasaka T, Baba K, et al. Long-term treatment of TAU-284 (betotastine besilate) on perennial allergic rhinitis [in Japanese]. Rinsho Iyaku 1997; 13(5): 1361–82

40.

Ishibashi Y, Harada S, Niimura M, et al. Long-term treatment of TAU-284 (betotastine besilate) on chronic urticaria [in Japanese]. Rinsho Iyaku 1997; 13(5): 1337–59

41.

Baba K. Results from post-marketing surveillance studies of Talion® tablets (bepotastine besilate) in patients with allergic rhinitis [in Japanese]. J New Rem Clin 2007 Feb 10; 56 (2 Suppl.): 10–33

42.

Baba S. Post-marketing surveillance study of Talion® tablets on pediatric allergic rhinitis [in Japanese]. Rinsho Iyaku 2002; 18(12): 1371–87

43.

Kawashima M. Post-marketing surveillance of Talion® tablets (bepotastine besilate) in patients with urticaria and pruritus associated with skin disease (eczema/dermatitis, prurigo, and cutaneous pruritus) [in Japanese]. J New Rem Clin 2007; 56(8): 93–107

44.

Kohda F, Furue M, Imafuku S. Immediate clinical effectiveness of bepotastine besilate for patients with urticaria [in Japanese]. Nishinihon J Dermatol 2006; 68(5): 544–7CrossRef

45.

Kubota Y, Moriue T, Nakai K, et al. Effects of bepotastine besilate on clinical usefulness with chronic urticaria based on patient-centered evaluation and patients’ QOL [in Japanese]. Nishinihon J Dermatol 2007; 69(5): 554–60CrossRef

46.

Dainichi T, Furue M, Murota H, et al. Assessment of the therapeutic effect of bepotastine besilate on chronic urticaria using a visual analogue scale (VAS) [in Japanese]. Skin Res 2007; 6(5): 513–8

47.

Furumura M, Kubota Y, Nakayama J. Efficacy and safety of bepotastine besilate in the treatment of chronic urticaria [in Japanese]. Nishinihon J Dermatol 2006; 68(1): 69–75CrossRef

48.

Horikawa T, Ueda M, Nishigori C, et al. Efficacy of bepotastine besilate in the management of senile pruritic diseases [in Japanese]. Skin Res 2005; 4(5): 475–80

49.

Takahashi H, Iizuka H. Usefulness and safety of bepotastine besilate for pruritic skin disorders [in Japanese]. Nishinihon J Dermatol 2006; 68(3): 284–7CrossRef

Titel: Oral Bepotastine
In Allergic Disorders
verfasst von: Katherine A. Lyseng-Williamson
Publikationsdatum: 01.08.2010
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11205880-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2010

Drug or Vaccine?

Laxative Abuse

Glatiramer Acetate

Oral Colchicine (Colcrys®)

Inactivated Split-Virion Seasonal Influenza Vaccine (Fluarix®)

Dexlansoprazole Modified Release